LRP5L

Across TCGA pan-cancer cohorts, LRP5L mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated LRP5L data layer compared with 23 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher LRP5L mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated LRP5L expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and COAD are the cancer types where LRP5L mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	III,IV	0.979	0.391	<.001	30	view →
CCRCC	DFS	Tertile	II,III,IV	0.793	0.457	.006	9	view →
COAD	DFS	Quartile	All	0.916	1.000	.048	6	view →
GBM	OS	Median	All	0.889	0.647	.015	4	view →
HNSC	DFS	Tertile	II,III,IV	0.880	0.985	.039	3	view →
LUAD	DFS	Tertile	All	1.000	0.588	.037	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

LRP5L–PDAC (DFS)

Open the PDAC breakdown →